Sisram MedicalSRAMF 60 Return-on-Tangible-Equity is 12.49% as of Dec. 2025, which is 9% below its 10-year median of 13.67. GuruFocus rates SRAMF with a GF Score™ of 60/100 and a GF Value™ of $0.97 (Significantly Undervalued). The stock has 5 warning signs investors should review. Among 757 Medical Devices & Instruments companies, Sisram Medical ranks better than 65.26% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Sisram Medical's annualized net income for the quarter that ended in Dec. 2025 was $25.2 Mil. Sisram Medical's average shareholder tangible equity for the quarter that ended in Dec. 2025 was $201.7 Mil. Therefore, Sisram Medical's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was 12.49%.
The historical rank and industry rank for Sisram Medical's Return-on-Tangible-Equity or its related term are showing as below:
SRAMF'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: 8.23 Med: 13.67 Max: 16.34
Current: 9.55
During the past 12 years, Sisram Medical's highest Return-on-Tangible-Equity was 16.34%. The lowest was 8.23%. And the median was 13.67%.
SRAMF's Return-on-Tangible-Equity is ranked better than 65.26% of 757
companies
in the Medical Devices & Instruments industry
Industry Median: 4.09
vs SRAMF: 9.55
Sisram Medical (OTCPK:SRAMF) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Sisram Medical Return-on-Tangible-Equity Related Terms
Sisram Medical Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Sisram Medical's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SRAMF vs ABT, SYK, MDT: Return-on-Tangible-Equity Comparison
For the Medical Devices subindustry, Sisram Medical's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sisram Medical Return-on-Tangible-Equity vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sisram Medical's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Sisram Medical's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Dec. 2025) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 12.49% mean?
Sisram Medical (SRAMF) has a Return-on-Tangible-Equity of 12.49% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sisram Medical and its competitors. This is near median its historical median of 13.67. Over the past decade, Sisram Medical's Return-on-Tangible-Equity has ranged from 8.23 to 16.34. According to the industry distribution chart, Sisram Medical ranks #263 out of 757 companies in the Medical Devices & Instruments industry, placing it in the top 34.7%.
Is Sisram Medical's Return-on-Tangible-Equity too high?
Sisram Medical's current Return-on-Tangible-Equity of 12.49% is near median its 10-year median of 13.67. Over the past 10 years, this metric has ranged from a low of 8.23 to a high of 16.34. The Medical Devices & Instruments industry median Return-on-Tangible-Equity is 4.09. Sisram Medical's value of 12.49% is 205.4% above this industry median. Based on the distribution chart, Sisram Medical ranks #263 out of 757 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Sisram Medical has a GF Score™ of 60/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sisram Medical's Return-on-Tangible-Equity compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Sisram Medical ranks #263 out of 757 companies for Return-on-Tangible-Equity. This puts Sisram Medical in the upper half of its industry. The industry median Return-on-Tangible-Equity is 4.09. Sisram Medical's value of 12.49% is 205.4% above this benchmark. Historically, Sisram Medical's own Return-on-Tangible-Equity has ranged from 8.23 to 16.34 over the past decade. While the company's 10-year median is 13.67 vs. the industry median of 4.09, Sisram Medical has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Medical Devices & Instruments company?
The median Return-on-Tangible-Equity among Medical Devices & Instruments companies is 4.09, based on 757 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sisram Medical's current Return-on-Tangible-Equity of 12.49% is 205.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sisram Medical and its competitors. For the Medical Devices & Instruments industry, the median Return-on-Tangible-Equity is 4.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sisram Medical's current Return-on-Tangible-Equity is 12.49%, which is near median its own 10-year median of 13.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sisram Medical stock overvalued right now?
Based on GuruFocus' analysis, Sisram Medical (SRAMF) is currently considered Significantly Undervalued. The stock's GF Value™ is $0.97, compared to a current price of $0.44 — trading 54.8% below its estimated fair value. The current Return-on-Tangible-Equity is 12.49%, which is near median its 10-year median of 13.67 and 205.4% above the Medical Devices & Instruments industry median of 4.09. Sisram Medical's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Sisram Medical (SRAMF), the current Return-on-Tangible-Equity is 12.49% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sisram Medical (SRAMF) Overvalued in 2026?
Based on GuruFocus' analysis, Sisram Medical stock appears to be undervalued.
The current stock price of $0.44 is trading 54.8% below its estimated GF Value™ of $0.97.
GuruFocus considers Sisram Medical to be Significantly Undervalued.
Key valuation signals for SRAMF:
Return-on-Tangible-Equity: 12.49% (near median its 10-year median of 13.67)
GF Value™: $0.97 vs. price of $0.44 (54.8% below fair value)
Industry Position: 205.4% above the Medical Devices & Instruments median (#263 of 757)
No single metric tells the full story. See the SRAMF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sisram Medical Ltd is an investment holding company specializing in medical technology for healthcare. The Company is involved in research, development, design, manufacture, sale and marketing of medical aesthetics and dental equipment, home use devices, injectables and cosmeceuticals products. The company's products include Soprano Titanium, Colibri technology, and others. Some of the company's brands are Alma, Soprano, Copulla, and LMNT. It operates through the following geographical segments: North America which is its key revenue generating market, Europe, Asia Pacific, Latin America, and the Middle East and Africa.
60GF Score
Get the complete analysis for SRAMF
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SRAMF has been successfully added to your 
